A novel method to improve the detection of cancer and metastases by peptide scanning under the protection of enzyme inhibitors: PepProtect 1 - PepProtect 1

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•Related to the medullary cancer of the thyroid:
•1. Histologically documented medullary cancer of the thyroid (MTC), or with elevated tumour marker (serum calcitonin) after previous treatment(s) for MTC
•Related to the patient:
•2. Life expectancy of more than 6 months.
•3. WHO performance status 0 or 1
•4. Male or female patients aged >18 years without upper age limit.

•1. Patients requiring treatment of the tumour urgently, before assessments required for the study can be completed.
•2. Pregnancy or breast feeding. Negative pregnancy test is required in female patients with child-bearing potential.
•3. Impaired renal function (eGFR <60 mL/min/1.73 m2)
•4. Impaired liver function (cirrhosis, grade B of the Child-Pugh classification; or hepatic enzyme levels >3x upper limit of normal)
•5. Known allergy or hypersensitivity to gastrin analogues or any of the components of the study medications.
•6. Any use of NEP-inhibitors within 30 days prior to the study; any use of experimental medication or other medication that potentially interfere with racecadotril or In111-DOTA-MG11.
•7. Any use of ACE inhibitors within 3 days of racecadotril administrations.

发起方